Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703493 | 0.84 | MAPT (0.42) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL1559285 | 0.82 | MAPT (0.45) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL28603762 | 0.81 | PDK2 (0.42) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL1662956 | 0.79 | CCNC (0.43) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL26836190 | 0.79 | L3MBTL1 (0.45) | MAPTLMNAL3MBTL1IKBKETBK1 | |
| SCHEMBL17385156 | 0.78 | PDK2 (0.39) | L3MBTL1ALDH1A1IKBKETBK1PDK2 | |
| SCHEMBL13102449 | 0.78 | ALPI (0.53) | LMNAALDH1A1IKBKETBK1PDK2 | |
| SCHEMBL1140165 | 0.78 | ALDH1A1 (0.49) | LMNAALDH1A1PKMIKBKETBK1 | |
| SCHEMBL1703729 | 0.78 | CCNC (0.45) | MAPTLMNAPDK2ALOX5AP | |
| SCHEMBL13739798 | 0.78 | MEN1 (0.42) | MAPTLMNAL3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654605-B | Bridged heterocyclic group substituted pyrimidine compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220348572-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2022-11-03 | — | — | US | disclosed |
| EP-4011865-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011865-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2022-06-15 | — | — | EP | disclosed |
| CN-112654605-A | Bridged heterocyclic group substituted pyrimidine compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2021027647-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2021027647-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2021-02-18 | — | — | WO | disclosed |
| CN-102666545-B | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor | CELLZOME LTD. (GB) | 2016-04-06 | — | — | CN | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| CN-103781780-B | As the heterocyclyl pyrimidines analogue of JAK inhibitor | CELLZOME LTD. (GB) | 2015-11-25 | — | — | CN | disclosed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013014162-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| CN-102666545-A | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | CELLZOME LTD | 2012-09-12 | — | — | CN | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | MAPT 2310/4885LMNA 2413/4885L3MBTL1 2652/4885 |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | MAPT 4393/4885LMNA 4606/4885L3MBTL1 3597/4885 |
| US-20220348572-A1 | BRIDGED HETEROCYCLYL-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | TYK2, JAK1, JAK2 | MAPT 3395/4885LMNA 3975/4885L3MBTL1 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.